Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Epizyme Inc (EPZM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 756,846
  • Shares Outstanding, K 79,168
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -134,310 K
  • 36-Month Beta 2.04
  • Price/Sales 55.33
  • Price/Cash Flow N/A
  • Price/Book 4.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.50
  • Number of Estimates 8
  • High Estimate -0.31
  • Low Estimate -0.66
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +3.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.14 +85.99%
on 12/24/18
10.47 -8.69%
on 01/14/19
+3.91 (+69.20%)
since 12/18/18
3-Month
5.14 +85.99%
on 12/24/18
10.47 -8.69%
on 01/14/19
+0.76 (+8.64%)
since 10/18/18
52-Week
5.14 +85.99%
on 12/24/18
21.40 -55.33%
on 03/13/18
-5.34 (-35.84%)
since 01/18/18

Most Recent Stories

More News
Clovis Oncology has the Best Relative Performance in the Biotechnology Industry (CLVS , CHRS , EPZM , CYTK , EXEL )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

CHRS : 11.72 (+5.49%)
CLVS : 24.00 (+7.29%)
EPZM : 9.56 (unch)
Epizyme to File NDA for Tazemetostat in Follicular Lymphoma

Epizyme (EPZM) announces that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma.

CELG : 86.27 (-0.37%)
MYGN : 29.67 (+3.67%)
RHHBY : 32.6100 (+0.59%)
EPZM : 9.56 (unch)
These 4 Healthcare Stocks Are Making Moves

CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / The is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will...

PHGI.CN : 0.870 (+1.16%)
PHGRF : 0.6833 (+5.19%)
NVAX : 2.05 (-2.38%)
SGYP : 0.28 (unch)
EPZM : 9.56 (unch)
Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma and Provides Pipeline Updates and 2019 Guidance

--Operating Runway Extended into the Second Quarter of 2020

EPZM : 9.56 (unch)
61.5% Return Seen to Date on SmarTrend Epizyme Inc Call (EPZM)

SmarTrend identified a Downtrend for Epizyme Inc (NASDAQ:EPZM) on June 15th, 2018 at $15.43. In approximately 6 months, Epizyme Inc has returned 61.49% as of today's recent price of $5.94.

EPZM : 9.56 (unch)
Epizyme Inc Has Returned 51.9% Since SmarTrend Recommendation (EPZM)

SmarTrend identified a Downtrend for Epizyme Inc (NASDAQ:EPZM) on June 15th, 2018 at $15.43. In approximately 6 months, Epizyme Inc has returned 51.90% as of today's recent price of $7.42.

EPZM : 9.56 (unch)
Why Is Epizyme (EPZM) Down 11.9% Since Last Earnings Report?

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EPZM : 9.56 (unch)
51.3% Return Seen to Date on SmarTrend Epizyme Inc Call (EPZM)

SmarTrend identified a Downtrend for Epizyme Inc (NASDAQ:EPZM) on June 15th, 2018 at $15.43. In approximately 5 months, Epizyme Inc has returned 51.31% as of today's recent price of $7.51.

EPZM : 9.56 (unch)
Epizyme Announces Conference Call to Discuss Corporate Updates

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call to discuss corporate updates...

EPZM : 9.56 (unch)
Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies

--Alliance Enhances Epizyme's Leadership in Oncology Epigenetics

EPZM : 9.56 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade EPZM with:

Business Summary

Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 9.98
1st Resistance Point 9.77
Last Price 9.56
1st Support Level 9.36
2nd Support Level 9.16

See More

52-Week High 21.40
Fibonacci 61.8% 15.19
Fibonacci 50% 13.27
Fibonacci 38.2% 11.35
Last Price 9.56
52-Week Low 5.14

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar